Epitalon and sleep: the pineal-gland connection

A careful look at the small Russian literature on a Phase-2 peptide tied to melatonin rhythms.

TL;DR

• Epitalon is a synthetic four-amino-acid peptide based on a natural pineal-gland extract called Epithalamin.
• Russian studies report effects on melatonin rhythm and sleep quality, but trials are small and rarely replicated outside Russia.
• FDA removed Epitalon from Category 2 on April 22, 2026. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list.

What it is

Epitalon (also written epithalon, epithalone) is a synthetic tetrapeptide — a chain of just four amino acid building blocks. It was developed at the St. Petersburg Institute of Bioregulation and Gerontology and modeled on Epithalamin, a natural extract from the pineal gland (in plain English: a pea-sized gland deep in the brain that releases melatonin at night). Think of the pineal as the body's bedtime bell. Epitalon was designed to nudge the bell back into rhythm when age has muted it.

How it works

The pineal gland releases melatonin in a wave that peaks during the dark hours. With age, this wave flattens — bedtime signal gets quieter. Russian studies report that Epitalon increases nighttime melatonin output and improves the timing of the rise. The proposed downstream effect is steadier circadian rhythm, which the literature ties to better sleep quality, blood pressure stability, and cellular stress markers (Anisimov et al., Neuroendocrinol Lett, 2003).

Who asks about it

People come to Epitalon after reading longevity content or hearing about the "telomere peptide." Many are older adults whose sleep has shifted — early waking, shallow rest, fragmented nights. They want something that addresses the upstream signal rather than another sedative.

What the research says

A handful of small Russian trials in older adults reported improvements in melatonin rhythm, reductions in age-related sleep complaints, and modest reductions in markers of oxidative stress over three- to six-month courses. One older-adult cohort showed about 7 in 10 patients reporting better sleep after a course of injections (Khavinson et al., Neuroendocrinol Lett, 2005). The studies are small (often 30–80 patients), short, and rarely double-blinded. Mainstream Western peer-reviewed replication is sparse. Reported side effects in those studies were minimal.

What to know before considering it

FDA removed Epitalon from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, Epitalon is not in any FDA 503A category and is not on the 503A bulks list. Material sold online as "research use only" is gray-market and unregulated for human use. The Russian literature is interesting but small. Older adults with sleep complaints should evaluate first-line, evidence-based options with a physician before reaching for a peptide that is not on the 503A bulks list.

The Halftime POV

Epitalon is one of the more interesting Phase-2 peptides — it points at a real biological lever (the pineal-melatonin axis) that does genuinely fade with age. The honest read of the data: small studies, mostly Russian, suggestive but not conclusive. If FDA adds it to the 503A bulks list, it earns a careful look — under a physician, with sleep tracking, and at a modest dose.

Related reading:

• Epitalon and telomere research, summarized
• Epitalon telomere-extension research, reviewed
• Category 2 peptides: what the classification means
• Melatonin, circadian rhythm, and aging

---

FAQ

Q: What is Epitalon? A: Epitalon is a synthetic four-amino-acid peptide modeled on Epithalamin, a natural pineal-gland extract. It was developed in Russia and is studied for effects on melatonin rhythms and cellular aging markers.

Q: Does Epitalon improve sleep? A: The small Russian studies report improvements in melatonin rhythm and sleep quality in older adults, with about 7 in 10 patients in one trial showing better self-reported sleep over a few weeks. Independent replication outside Russia is limited.

Q: Is Epitalon available in the United States? A: FDA removed Epitalon (epithalon) from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, Epitalon is not in any FDA 503A category and is not on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding Epitalon to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.

---

Disclaimer

Several peptides discussed in this article — including Epitalon (epithalon) — were previously in FDA's Category 2. FDA removed them from Category 2 on April 22, 2026. As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• Epithalon effects on melatonin and aging — Neuroendocrinol Lett, 2003
• Peptide regulation of aging and longevity in older adults — Neuroendocrinol Lett, 2005

---

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.